Pulmonary hypertension:

Indications for: REVATIO INJECTION

Pulmonary arterial hypertension (PAH) (WHO Group I) to improve exercise ability and delay clinical worsening, in adults who are temporarily unable to take oral Revatio.

Adult Dosage:

Give by IV bolus inj. 10mg three times daily.

Children Dosage:

Not recommended.

REVATIO INJECTION Contraindications:

Concomitant organic nitrates, riociguat.

REVATIO INJECTION Warnings/Precautions:

Pulmonary veno-occlusive disease: not recommended. PAH secondary to sickle cell anemia (risk of vaso-occlusive crisis). Underlying conditions that could be affected by vasodilatory effects (eg, concomitant antihypertensive therapy, BP<90/50, fluid depletion, severe left ventricular outflow obstruction, autonomic dysfunction). Risk of non-arteritic anterior ischemic optic neuropathy; monitor for sudden vision loss. Retinitis pigmentosa: not recommended. Anatomical penile deformation. Predisposition to priapism. Severe hepatic impairment. Active peptic ulcer. Bleeding disorders. Elderly. Pregnancy. Nursing mothers.


Phosphodiesterase type 5 inhibitor (cGMP-specific).


See Contraindications. Hypotension with nitrates. Concomitant strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, ritonavir): not recommended. Antagonized by moderate to strong CYP3A4 inducers (eg, bosentan).

Adverse Reactions:

Headache, dyspepsia, flushing, pain in limb, myalgia, back pain, diarrhea; priapism, hypotension, vision or hearing loss.


Hepatic (CYP3A, CYP2C9).

Drug Elimination:

Fecal (~80%), renal (13%).

Generic Drug Availability:

Tabs (YES); Susp, inj (NO)

How Supplied:

Tabs—90; Susp—112mL (w. bottle adapter, oral syringe); Single-use vial (12.5mL)—1